The Phase 3 clinical trial for Trappsol® Cyclo™ by Cyclo Therapeutics targeting Niemann-Pick Disease Type C1, a rare and fatal genetic disorder, has reached full enrollment. The 48-week interim analysis is anticipated to unveil results around mid-2025. This trial specifically aims to assess the effectiveness of TransportNPC™ in treating this illness. Niemann-Pick Disease Type C1 is a severe condition, and the study's outcome could potentially bring hope to individuals affected by it.
